US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
Potrebbe interessarti anche
Chi ha guadagnato
Ultime notizie crypto
Una certa balena con una posizione short significativa in BTC sta pianificando di longare intorno ai 67.000$, con gli short che attualmente mostrano un profitto di 26,83 milioni di$.
Wintermute: La struttura del mercato sta migliorando, i token mainstream non sono più fragili
Una holding di balene forte di 'Shorting Shitcoins' Nets 6,417 milioni di dollari in guadagni non realizzati, il profitto totale del conto supera i 78,86 milioni di dollari
La Polonia rifiuta una regolamentazione rigorosa nel "Cryptocurrency Market Act"
Il governo del Regno Unito sta considerando di vietare le criptovalute per le donazioni politiche per evitare interferenze straniere
Assistenza clienti:@weikecs
Cooperazione aziendale:@weikecs
Trading quantitativo e MM:[email protected]
Servizi VIP:[email protected]